The medication is gradually increased over several weeks, starting at 0.25 mg weekly for the first four weeks, then typically increasing to 0.5 mg, with potential further titration to 1 mg or 2 mg depending on glycaemic control and tolerability
Peptides can help decrease inflammation because of their anti-inflammatory properties, helping our bodies recover faster and allowing our bodies to focus on burning fat rather than working harder than necessary to recover
This risk has only been observed in animal studies
Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected as new entrants including Boehringer Ingelheim, Amgen, Pfizer and Roche offer novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly)
Some patients notice enhanced appetite control due to Mounjaros dual mechanism
Questions To Ask Your Clinician Before Switching Making an informed decision about your treatment, whether you are starting a GLP-1 for the first time or considering a switch, begins with a thorough conversation with your healthcare team
